Eligibility Criteria for Liver Metastasis from Colorectal Cancer Clinical Trial

Patients with confirmed liver metastasis from colon cancer diagnosed by organization or cellular pathology.\n2. Patients who have previously received first-line chemotherapy and achieved disease control (PR+SD) assessed by RECIST 1.1.\n3. Patients with liver metastasis from colorectal cancer who have undergone curative local treatment (surgery, ablation, SBRT) and achieved no evidence of disease (NED). NED is defined as: a. After local treatment, no residual tumor or tumor activity is observed in the primary or metastatic lesions on CT, MRI, PET-CT. b. No cancer cells are found in the biopsy of suspicious lesions.\n4. Patients who have completed routine adjuvant chemotherapy (such as 4-8 cycles of Xelox regimen, 6-12 cycles of FOLFOX regimen, or discontinued fluoropyrimidine monotherapy) after achieving NED and evaluated as disease-free.\n5. The time since the last chemotherapy does not exceed 2 months.\n6. Performance status (ECOG) score \u003c= 2.\n7. Age between 18 and 75 years (including 18 and 75 years).\n8. Hematology: WBC \u003e 3\u00d710^9 /L; PLT \u003e 80\u00d710^9 /L; Hb \u003e 90g/L.\n9. Liver function: ALT and AST \u003c= 2.5\u00d7ULN; bilirubin \u003c= 1.5\u00d7ULN.\n10. Kidney function: Serum creatinine \u003c= 1.5\u00d7ULN or creatinine clearance rate (CCr) \u003e= 60ml/min.\n11. Signed informed consent, patients willing to receive treatment according to this protocol, able to adhere to medication, and have good compliance.